Tiratricol

drugbox
IUPAC_name = 2- [4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]
acetic acid

---

CAS_number = 51-24-1
ATC_prefix = H03
ATC_suffix = AA04
ATC_supplemental = ATC|D11|AX08
PubChem = 5803
DrugBank =
C = 14 | H = 9 | I = 3 | O = 4
molecular_weight = 621.932 g/mol
synonyms = 3,3',5-triiodothyroacetic acid
TRIAC
bioavailability =
protein_bound = Presumed high
metabolism = Hepatic glucuronidation
elimination_half-life =
excretion = Biliary
pregnancy_AU =
pregnancy_US =
pregnancy_category=
legal_AU =
legal_CA =
legal_UK =
legal_US =
legal_status =
routes_of_administration =

Tiratricol (also known as TRIAC or triiodothyroacetic acid) is a thyroid hormone analogue. It is indicated in the management of thyroid hormone resistance syndrome [cite journal |author=Carvalho GA, Ramos HE |title= [Thyroid hormone resistance syndrome] |language=Portuguese |journal=Arq Bras Endocrinol Metabol |volume=48 |issue=1 |pages=83–92 |year=2004 |pmid=15611821 |doi=/S0004-27302004000100010 PDFlink| [http://www.scielo.br/pdf/abem/v48n1/19522.pdf Free full text] |95.3 KiB ] and is used, in combination with levothyroxine, to suppress thyroid-stimulating hormone production in patients with thyroid cancer.

Tiratricol has also been widely marketed, under various trade names, as a weight loss aid. In 1999 and 2000, the United States Food and Drug Administration and Health Canada both issued warnings to the public regarding the use of dietary supplements containing tiratricol. [cite press release | url = http://www.fda.gov/bbs/topics/ANSWERS/ANS01057.html | title = FDA Warns Against Consuming Dietary Supplements Containing Tiratricol | date = November 21 2000 | accessdate = 2007-08-08 | publisher = U.S. Food and Drug Administration] [cite press release | url = http://www.hc-sc.gc.ca/ahc-asc/media/advisories-avis/1999/1999_143_e.html | title = Health Canada issues warning on products containing Tiratricol (TRIAC) | date = December 2 1999 | accessdate = 2007-08-08 | publisher = Health Canada]

Legal status

Tiratricol is not approved for sale in Canada or the United States. It was once an approved drug in Brazil, but its marketing authorization was suspended in 2003, effectively prohibiting its sale. [cite web | url = http://www.endocrino.org.br/noticia_g_exibe.php?id=9 | title = Anvisa suspende Tiratricol | language = Portuguese | date = | accessdate = 2007-08-08 | publisher = Brazilian Society of Endocrinology and Metabolism]

References